ATE205531T1 - Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum - Google Patents

Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum

Info

Publication number
ATE205531T1
ATE205531T1 AT94909270T AT94909270T ATE205531T1 AT E205531 T1 ATE205531 T1 AT E205531T1 AT 94909270 T AT94909270 T AT 94909270T AT 94909270 T AT94909270 T AT 94909270T AT E205531 T1 ATE205531 T1 AT E205531T1
Authority
AT
Austria
Prior art keywords
inhibition
growth
cell activation
antibodies
cd2a
Prior art date
Application number
AT94909270T
Other languages
English (en)
Inventor
Herve Bazin
Dominique Latinne
Original Assignee
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Catholique Louvain filed Critical Univ Catholique Louvain
Application granted granted Critical
Publication of ATE205531T1 publication Critical patent/ATE205531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94909270T 1993-03-05 1994-03-04 Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum ATE205531T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2700893A 1993-03-05 1993-03-05
US11903293A 1993-09-09 1993-09-09
PCT/IB1994/000043 WO1994020619A1 (en) 1993-03-05 1994-03-04 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
ATE205531T1 true ATE205531T1 (de) 2001-09-15

Family

ID=26701922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909270T ATE205531T1 (de) 1993-03-05 1994-03-04 Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum

Country Status (10)

Country Link
EP (1) EP0687300B1 (de)
JP (2) JP3711143B2 (de)
AT (1) ATE205531T1 (de)
AU (1) AU686600B2 (de)
CA (1) CA2157500C (de)
DE (1) DE69428272T2 (de)
DK (1) DK0687300T3 (de)
ES (1) ES2164699T3 (de)
PT (1) PT687300E (de)
WO (1) WO1994020619A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
CA2262546C (en) * 1996-08-16 2009-03-17 Biotransplant, Inc. Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
KR100516561B1 (ko) 1996-12-06 2005-09-22 아벤티스 파마슈티칼스 인크. 사람 리파제-유사 유전자에 의해 암호화된 폴리펩타이드, 조성물 및 방법
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
JP4808841B2 (ja) * 1997-07-18 2011-11-02 バイオトランスプラント，インコーポレイテッド Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法
ATE439137T1 (de) 1997-11-14 2009-08-15 Gen Hospital Corp Behandlung von hämatologischen störungen
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
KR101240206B1 (ko) 2010-10-05 2013-03-06 고려대학교 산학협력단 자연살상 세포-매개 면역반응 억제용 조성물
BR112020010816A2 (pt) * 2017-11-29 2020-11-10 Magenta Therapeutics, Inc. composições e métodos para a depleção de células de cd2+
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody

Also Published As

Publication number Publication date
JP4195453B2 (ja) 2008-12-10
AU686600B2 (en) 1998-02-12
DK0687300T3 (da) 2001-12-31
CA2157500A1 (en) 1994-09-15
PT687300E (pt) 2002-03-28
AU6218194A (en) 1994-09-26
EP0687300B1 (de) 2001-09-12
WO1994020619A1 (en) 1994-09-15
DE69428272T2 (de) 2002-06-27
JP3711143B2 (ja) 2005-10-26
JP2005239725A (ja) 2005-09-08
ES2164699T3 (es) 2002-03-01
JPH08507438A (ja) 1996-08-13
EP0687300A1 (de) 1995-12-20
CA2157500C (en) 2005-08-16
DE69428272D1 (de) 2001-10-18

Similar Documents

Publication Publication Date Title
EP1003552A4 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGENE ZUR HEMMUNG VON T-ZELL AKTIVIERUNG UND WACHSTUM
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
DK0592521T3 (da) Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler
EP0751992A4 (de) Vaskularer endothelialer wachstumsfaktor 2
DE68925226D1 (de) Monoklonale Antikörper
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
NO973875L (no) Fremgangsmåte for stimulering av en immunrespons
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE3786173D1 (de) Menschlicher monoklonaler antikoerper und arzneimittel zur prophylaxe und behandlung von infektioesen krankheiten.
ATE156711T1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
DE69010897D1 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
ATE99333T1 (de) Immunogen und seine verwendung zur gewinnung von antikoerpern gegen haemoglobin a1c.
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee